High Expression of the Thalidomide-Binding Protein Cereblon (CRBN) Is Associated with Improved Clinical Response in Patients with Multiple Myeloma Treated with Lenalidomide and Dexamethasone

被引：3
|
作者：
Heintel, Daniel [1 ]
Bolomsky, Arnold [1 ]
Schreder, Martin [1 ]
Pfeifer, Sabine [1 ]
Zojer, Niklas [1 ]
Jaeger, Ulrich [2 ]
Ludwig, Heinz [1 ]
机构：
[1] Wilhelminenhosp, Ctr Oncol & Hematol, Dept Internal Med 1, Vienna, Austria
[2] Med Univ Vienna, Vienna, Austria
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
10.1182/blood.V118.21.2879.2879
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1242 / 1243
页数：2
相关论文
共 50 条
  • [41] Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation
    Terragna, Carolina
    Renzulli, Matteo
    Remondini, Daniel
    Tagliafico, Enrico
    Di Raimondo, Francesco
    Patriarca, Francesca
    Martinelli, Giovanni
    Roncaglia, Enrica
    Masini, Luciano
    Tosi, Patrizia
    Zamagni, Elena
    Tacchetti, Paola
    Ledda, Antonio
    Brioli, Annamaria
    Angelucci, Emanuele
    Testoni, Nicoletta
    Marzocchi, Giulia
    Galieni, Piero
    Gozzetti, Alessandro
    Martello, Marina
    Dico, Flores
    Mancuso, Katia
    Cavo, Michele
    ANNALS OF HEMATOLOGY, 2013, 92 (09) : 1271 - 1280
  • [42] IKZF1/3 Protein Expressions Are Associated with a Better Survival in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide
    Pourabdollah, Maryam
    Bahmanyar, Mohammad
    Atenafu, Eshetu G.
    Reece, Donna
    Chang, Hong
    BLOOD, 2016, 128 (22)
  • [43] Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone
    Avet-Loiseau, H.
    Soulier, J.
    Fermand, J-P
    Yakoub-Agha, I.
    Attal, M.
    Hulin, C.
    Garderet, L.
    Belhadj, K.
    Dorvaux, V.
    Minvielle, S.
    Moreau, P.
    LEUKEMIA, 2010, 24 (03) : 623 - 628
  • [44] Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
    Meletios Dimopoulos
    Michael Wang
    Vladimir Maisnar
    Jiri Minarik
    William Bensinger
    Maria-Victoria Mateos
    Mihaela Obreja
    Julie Blaedel
    Philippe Moreau
    Journal of Hematology & Oncology, 11
  • [45] Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
    Dimopoulos, Meletios
    Wang, Michael
    Maisnar, Vladimir
    Minarik, Jiri
    Bensinger, William
    Mateos, Maria-Victoria
    Obreja, Mihaela
    Blaedel, Julie
    Moreau, Philippe
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [46] OVERALL RESPONSE RATE OF PATIENTS WITH REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE AND LOW DOSE DEXAMETHASONE AFTER LENALIDOMIDE FAILURE: INTERIM RESULTS OF THE POSEIDON STUDY
    Dechow, T.
    Aldaoud, A.
    Hurtz, H. J.
    Knauf, W.
    Groschek, M.
    Hansen, R.
    Mittermueller, J.
    Grebhardt, S.
    Boller, E.
    Potthoff, K.
    HAEMATOLOGICA, 2016, 101 : 540 - 540
  • [47] "REAL WORLD" DATA FROM PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE BEEN TREATED WITH LENALIDOMIDE AND DEXAMETHASONE, ACCORDING TO THE STANDARD CLINICAL PRACTICE
    Katodritou, E.
    Anagnostopoulos, A.
    Vadikolia, C.
    Lalayianni, C.
    Kotsopoulou, M.
    Repousis, P.
    Megalakaki, A.
    Rekleiti, A.
    Dadakaridou, M.
    Papageorgiou, G.
    Kyrtsonis, M.
    Matsouka, P.
    Giannakoulas, N.
    Kyriakou, D.
    Karras, G.
    Anagnostopoulos, N.
    Michalis, E.
    Briasoulis, E.
    Hatzimichael, E.
    Spanoudakis, E.
    Zikos, P.
    Tsakiridou, A.
    Tsionos, K.
    Anargyrou, K.
    Symeonidis, A.
    Maniati, A.
    Terpos, E.
    HAEMATOLOGICA, 2013, 98 : 604 - 604
  • [48] Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)
    Joseph, Nisha S.
    Kaufman, Jonathan L.
    Dicamillo, Sara
    Roberts, Danielle
    Gupta, Vikas A.
    Hofmeister, Craig C.
    Dhodapkar, Madhav V.
    Boise, Lawrence H.
    Lonial, Sagar
    Nooka, Ajay K.
    BLOOD, 2023, 142
  • [49] A RETROSPECTIVE ANALYSIS OF THE CLINICAL RESPONSE RATE AND RENAL REVERSIBILITY OF THALIDOMIDE BASED REGIMES IN PATIENTS WITH MULTIPLE MYELOMA AND ASSOCIATED RENAL IMPAIRMENT
    Vatopoulou, T.
    Jones, J.
    Basnayake, K.
    Corbett, T.
    HAEMATOLOGICA, 2012, 97 : 612 - 613
  • [50] High CD47 Protein Expression Is Associated with Inferior Survival in Patients with Multiple Myeloma
    Portrabdollah, Maryam
    Bahmanyar, Mohammad
    Atenafu, Eshetu G.
    Reece, Donna
    Chang, Hong
    LABORATORY INVESTIGATION, 2017, 97 : 371A - 371A
12345